Join +750K new investors every month who copy stock picks from billionaire's portfoliosSign Up Free

IO Biotech And 2 Other Stocks Under $2 Insiders Are Buying

Published 27/11/2023, 11:26
© Reuters.  IO Biotech And 2 Other Stocks Under $2 Insiders Are Buying
VNRX
-

Benzinga - by Lisa Levin, Benzinga Editor.

The Dow Jones closed higher by over 100 points on Friday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga's insider transactions platform.

VolitionRx

  • The Trade: VolitionRx Limited (NYSE: VNRX) Director Guy Archibald Innes acquired a total of 20,000 shares an average price of $0.71. To acquire these shares, it cost around $14,200.
  • What’s Happening: EF Hutton reiterated VolitionRX with a Buy and maintained a $4.5 price target.
  • What VolitionRx Does: VolitionRX Ltd is a United states based epigenetics company that applies its Nucleosomics platform through its subsidiaries to develop simple, easy-to-use, cost effective blood tests to help diagnose and monitor a range of life-altering diseases including some cancers and diseases associated with NETosis such as sepsis and COVID-19.
KORE Group Holdings
  • The Trade: KORE Group Holdings, Inc. (NYSE: KORE) Director, Pres., Chief Executive Officer Romil Bahl acquired a total of 12,514 shares at an average price of $0.62. To acquire these shares, it cost around $7,708.
  • What’s Happening: KORE Group reported worse-than-expected third-quarter financial results and issued FY23 revenue guidance below estimates.
  • What KORE Group Holdings Does: Kore Group Holdings Inc provides Internet of Things (IoT) solutions and services. In addition to providing critical services to customers globally, it enables them to manage, deploy, and scale their IoT applications and use cases.
Check This Out: Top 5 Tech And Telecom Stocks That Could Blast Off In Q4

IO Biotech

  • The Trade: IO Biotech, Inc. (NASDAQ: IOBT) Chief Accounting Officer Brian Burkavage acquired a total of 10,000 shares at an average price of $1.01. The insider spent around $10,125 to buy those shares.
  • What’s Happening: IO Biotech posted a narrower-than-expected quarterly loss.
  • What IO Biotech Does: IO Biotech Inc is a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on T-win technology platform.

Don’t forget to check out our premarket coverage here

© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Read the original article on Benzinga

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.